- Home
- IHT vs NRSN Comparison
IHT vs NRSN Comparison
Compare IHT & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IHT | NRSN |
|---|---|---|
| Founded | 1971 | 2017 |
| Country | United States | Israel |
| Employees | N/A | 16 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 16.8M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | IHT | NRSN |
|---|---|---|
| Price | $1.74 | $0.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 17.6K | ★ 185.6K |
| Earning Date | 05-12-2026 | 03-31-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $7,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $0.95 | $0.39 |
| 52 Week High | $4.24 | $1.33 |
Technical Indicators
Market Signals| Indicator | IHT | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 33.34 |
| Support Level | $1.01 | N/A |
| Resistance Level | $1.87 | $0.74 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 46.43 | 33.65 |
Price Performance
Historical ComparisonAbout IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.